GLS and neoplasm: While selective allosteric glutaminase (GLS1) inhibitors such as CB-839 (telaglenastat) and bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) exhibit enhanced tumor selectivity and improved therapeutic windows, the metabolic glutamine addiction of immune effector cells poses inherent risks of treatment-related immunosuppression, particularly under conditions of prolonged GLS1 blockade [152,153].